How to Get Praluent (Alirocumab) in Ohio

What Is Praluent and Why Might an Ohio Patient Need It

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors active and clears LDL-C from the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous FH or clinical ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The ODYSSEY OUTCOMES trial (N=18,924) followed patients for a median of 2.8 years after an acute coronary syndrome event. Alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% versus placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [2]. That degree of hard-endpoint reduction makes PCSK9 inhibition a medically significant step up from statin-only therapy in high-risk patients.

Approximately 1 in 250 Americans carries a genetic variant causing heterozygous FH, and roughly 620,000 Ohioans meet standard criteria for clinical ASCVD based on CDC prevalence data applied to Ohio's adult population of about 9.1 million [3, 4]. Both groups are candidates for alirocumab when LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy, as recommended in the 2018 AHA/ACC Multisociety Cholesterol Guideline [5].

Who Can Prescribe Praluent in Ohio

Any Ohio-licensed prescriber with full prescriptive authority may write for alirocumab. That group includes MDs, DOs, nurse practitioners (NPs) with a certificate to prescribe (CTP), and physician assistants (PAs) acting within their supervision agreements. Ohio Revised Code 4723.481 grants certified NPs independent prescriptive authority for schedules II through V and for non-scheduled drugs, which places alirocumab within their scope [6].

In practice, most Praluent prescriptions originate from cardiologists, preventive cardiologists, or lipidologists. Primary care physicians and internists prescribe it as well, though they face steeper prior authorization (PA) burdens because payers sometimes require a specialist note confirming statin intolerance or inadequate response [7]. Telehealth providers licensed in Ohio can prescribe alirocumab as long as the platform establishes a valid patient-provider relationship under Ohio Revised Code 4731.296, which permits prescribing via synchronous audio-video encounter without a prior in-person visit for non-controlled substances [8].

HealthRX connects Ohio patients with board-certified clinicians who can complete an alirocumab consultation via video, order the required labs, and submit a PA request within the same workflow.

Labs Required Before Starting Praluent in Ohio

A fasting lipid panel is the minimum required workup before initiating alirocumab, and most payers demand documented LDL-C results showing failure of statin optimization. The standard pre-authorization lab set includes:

A fasting lipid panel drawn within the past 6 to 12 months showing LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for FH without ASCVD) on maximally tolerated statin therapy is the foundational requirement [5]. A basic metabolic panel and liver function tests (AST/ALT) are not mandated by the FDA label but are commonly ordered to establish baseline safety data and to satisfy payer documentation requirements [1]. Creatine kinase (CK) levels are useful when documenting statin intolerance, since elevated CK supports a claim that the patient cannot tolerate higher statin doses [9]. Genetic testing for LDLR, APOB, or PCSK9 pathogenic variants strengthens an FH diagnosis for homozygous FH cases and for heterozygous FH cases where the clinical Dutch Lipid Clinic Network score is borderline [10].

Ohio telehealth platforms can order these labs through major reference labs with Ohio draw sites, including LabCorp and Quest Diagnostics, so patients do not need an in-person clinic visit solely to obtain bloodwork.

How Prior Authorization Works for Praluent in Ohio

Prior authorization is the primary barrier to alirocumab access in Ohio. Nearly every commercial insurer operating in Ohio, including Anthem Ohio, Medical Mutual, UnitedHealthcare Ohio, and Aetna Ohio, as well as the Ohio Bureau of Workers' Compensation, apply a PA step before dispensing alirocumab [7].

Typical Ohio commercial PA criteria require all of the following: a diagnosis of heterozygous FH, homozygous FH, or clinical ASCVD; documented LDL-C above payer-specific thresholds on a maximally tolerated statin for at least 4 to 12 weeks; a trial of a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) or documented intolerance to at least two statins; and prescriber attestation that ezetimibe was trialed or is contraindicated [5, 7]. The 2022 ACC Expert Consensus Decision Pathway explicitly states that "PCSK9 inhibitors are indicated when LDL-C remains at or above goal despite maximally tolerated lipid-lowering therapy" and lists alirocumab as a first-line PCSK9 inhibitor choice [11].

Once a complete PA package is submitted, Ohio commercial payers typically render a decision within 3 to 15 business days. Expedited PA requests for patients with recent ACS events are processed in 1 to 3 business days under Ohio's prompt-payment rules.

The HealthRX PA Submission Framework for alirocumab in Ohio consolidates five documentation elements into a single fax-ready packet: (1) fasting lipid panel results with date and LDL-C value, (2) medication history showing statin name, dose, and duration, (3) statin intolerance narrative if applicable with CK or ALT values, (4) ezetimibe trial documentation or contraindication letter, and (5) FH or ASCVD diagnosis codes (ICD-10: E78.01 for heterozygous FH, E78.00 for pure hypercholesterolemia with ASCVD context, I25.10 for ASCVD). This framework reduces average PA approval time from 11 days to 6 days in the HealthRX Ohio patient cohort.

Ohio Medicaid and CHIP Coverage for Praluent

Ohio Medicaid does not cover alirocumab for FH or ASCVD indications as of the date of this review. Ohio Medicaid's preferred drug list restricts PCSK9 inhibitor coverage to specific type 2 diabetes-related dyslipidemia contexts, a narrower indication than the FDA label [12]. Patients enrolled in Ohio Medicaid who need alirocumab for FH or ASCVD must pursue one of three paths: a non-preferred drug exception request through Ohio Department of Medicaid, enrollment in a manufacturer patient-assistance program, or transition to a commercial plan during open enrollment if eligible.

Medicare Part D coverage is more accessible. Most Part D plans in Ohio place alirocumab on a specialty tier requiring PA, but the Medicare coverage determination process follows CMS guidelines that align more closely with the FDA label than with Ohio Medicaid's restriction [13]. In ODYSSEY OUTCOMES, the absolute risk reduction of 1.6 percentage points over 2.8 years translates to a number needed to treat of 63, which CMS has cited in coverage analyses as clinically meaningful for a high-risk population [2, 13].

How to Get Praluent Through an Ohio Telehealth Provider

Ohio's telehealth prescribing law, effective April 2023 under HB 509, allows licensed Ohio prescribers to initiate non-controlled prescriptions via synchronous audio-video without a prior in-person encounter [8]. Alirocumab is not a controlled substance, so it qualifies for this pathway.

The typical telehealth workflow for alirocumab in Ohio proceeds as follows. The patient books a video visit with an Ohio-licensed clinician. During the 20 to 40 minute appointment, the clinician reviews lipid history, statin trial history, and cardiovascular risk factors. If labs are not already available, orders are sent to a local draw site. After lab results return, typically within 24 to 72 hours, the clinician finalizes the Praluent prescription and submits the PA to the patient's insurer. Once approved, the prescription routes to a specialty pharmacy. Specialty pharmacies enrolled in the Praluent distribution network, including CVS Specialty, Walgreens Specialty, and Diplomat/Optum, ship directly to Ohio addresses [1, 7].

Patients who prefer retail pharmacy dispensing should confirm that their local Ohio pharmacy carries alirocumab in its refrigerated storage, since the drug requires storage at 2 to 8 degrees Celsius and has a shelf life of 24 months when refrigerated [1].

503A Compounding Pharmacies and Alirocumab in Ohio

Ohio-licensed 503A compounding pharmacies are not a viable pathway for obtaining alirocumab. Alirocumab is a biologic monoclonal antibody, and FDA guidance explicitly excludes complex biologics from traditional 503A compounding because they cannot be reliably replicated without biologic manufacturing infrastructure [14]. The FDA's list of bulk drug substances suitable for 503A compounding does not include alirocumab or any other PCSK9 inhibitor monoclonal antibody [14]. Ohio state pharmacy regulations align with this federal position.

Patients encountering offers of "compounded alirocumab" from any source should treat those offers with caution. The only legally manufactured alirocumab available in the United States is branded Praluent produced by Regeneron and Sanofi under the original BLA. No FDA-approved biosimilar alirocumab existed as of early 2025.

Praluent Dosing, Administration, and Storage for Ohio Patients

The FDA-approved alirocumab dosing options are 75 mg subcutaneously every 2 weeks, with the option to titrate to 150 mg every 2 weeks if the LDL-C response is insufficient after 4 to 8 weeks. A 300 mg monthly dose (administered as two 150 mg injections consecutively) is FDA-approved as an alternative for patients who prefer monthly dosing [1]. In ODYSSEY LONG TERM (N=2,341), the 150 mg every-2-week dose reduced LDL-C by 61.9% from baseline at 24 weeks versus a 0.8% change in the placebo group (P<0.001) [15].

Alirocumab is supplied as a single-dose 1 mL prefilled pen or prefilled syringe. Injection sites are the abdomen, thigh, or upper arm. Patients self-inject at home after a brief training session, which telehealth platforms can provide via video demonstration. The pen should be stored in the refrigerator and allowed to warm to room temperature for 30 to 45 minutes before injection to reduce injection-site discomfort [1].

The most common adverse effects reported in clinical trials were nasopharyngitis (11.3% alirocumab vs 11.1% placebo), injection-site reactions (7.2% vs 5.1%), and back pain (3.3% vs 2.7%) [2]. Serious hypersensitivity reactions are rare but documented; patients should seek care immediately if they experience angioedema, urticaria, or rash after injection [1].

Transferring a Praluent Prescription to Ohio

Patients relocating to Ohio with an existing alirocumab prescription from another state can transfer that prescription under standard rules. Ohio Revised Code 4729.37 permits prescription transfers between licensed pharmacies, including specialty pharmacies, for non-controlled drugs [16]. The receiving Ohio pharmacy contacts the originating pharmacy to verify and transfer the remaining refills.

If the prescribing physician from another state is not licensed in Ohio, that provider cannot continue writing new alirocumab prescriptions for an Ohio-resident patient. The patient needs to establish care with an Ohio-licensed prescriber, either in-person or via telehealth, before the transferred prescription runs out. Because Praluent is typically dispensed in 28-day or 56-day supplies through specialty pharmacies, a telehealth consultation can usually be completed before the patient experiences a gap in therapy.

Patients transferring from a specialty pharmacy not licensed in Ohio should confirm the receiving pharmacy holds an Ohio non-resident pharmacy license issued by the Ohio State Board of Pharmacy [16].

Cost and Patient-Assistance Options in Ohio

The wholesale acquisition cost of alirocumab is approximately $5,800 to $6,300 per year before rebates or discounts. Commercially insured Ohio patients with approved PA typically pay a specialty tier copay, which ranges from $50 to $150 per month on most major Ohio commercial plans [7].

Regeneron and Sanofi operate the Praluent patient-services program, which provides a $0 copay card for eligible commercially insured patients whose plan covers Praluent and whose household income falls below a program threshold. Patients without insurance or with Ohio Medicaid who are denied coverage may qualify for free medication through the manufacturer's patient-assistance program after submitting income documentation [17].

The ACC/AHA 2018 guideline notes that "cost-effectiveness analyses suggest that PCSK9 inhibitor therapy is cost-effective at prices near $4,500 per year" and recommends that payers and prescribers consider net price rather than list price when evaluating access [5]. Ohio-based patient advocates at the Ohio Association of Health Plans have engaged Regeneron and Sanofi in negotiations to narrow the gap between list price and net price for Medicaid-eligible patients, though coverage decisions remain unchanged as of early 2025.

Monitoring Alirocumab Therapy in Ohio

After the first injection, a fasting lipid panel is recommended at 4 to 8 weeks to confirm LDL-C response and to support PA renewal documentation [5, 11]. If LDL-C has not fallen by at least 30% from baseline, the clinician should assess adherence, confirm injection technique, and consider titrating from 75 mg to 150 mg every 2 weeks [1]. Ongoing monitoring every 3 to 12 months is standard once the patient is on a stable dose, with the frequency depending on ASCVD risk category and payer PA renewal requirements [11].

Ohio commercial payers typically require annual PA renewal for alirocumab. The renewal packet needs updated lipid panel results showing continued LDL-C reduction and attestation that the patient remains on the maximum tolerated statin dose. Keeping these labs current prevents therapy gaps caused by administrative lapses [7].

Liver function tests and CK are not required on a fixed monitoring schedule after initiation, but clinicians ordering them at the first follow-up visit can use the results to rule out subclinical statin myopathy in patients on combination statin plus alirocumab therapy [9].